Affinity-Purified Respiratory Syncytial Virus Antibodies from Intravenous Immunoglobulin Exert Potent Antibody-Dependent Cellular Cytotoxicity

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Gupta, Nimesh ^a,b,c   LeGoff, Jerome ^d,e   Chamat, Soulaima ^f   Mercier Delarue, Severine ^e   Touzelet, Olivier ^g   Power, Ultan F ^g   Kazatchkine, Michel D ^h   Simon, Francois ^d,e   Lacroix Desmazes, Sebastien ^a,b,c,i   Bayry, Jagadeesh ^a,b,c,i   Kaveri, Srinivas V ^a,b,c,i  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f LEBANESE UNIVERSITY   (Lebanon)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^h UNAIDS   (Switzerland)

ⁱ INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BLOOD DONOR; COMPLEMENT DEPENDENT CYTOTOXICITY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN PURIFICATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE; CHILD; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84880403672     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069390     Document Type: Article

References (26)

1. Falsey AR, Cunningham CK, Barker WH, Kouides RW, Yuen JB, et al. (1995) Respiratory syncytial virus and influenza A infections in the hospitalized elderly. The Journal of infectious diseases 172: 389-394.
2. Panitch HB, (2001) Bronchiolitis in infants. Current opinion in pediatrics 13: 256-260.
3. Hall CB, (2001) Respiratory syncytial virus and parainfluenza virus. The New England journal of medicine 344: 1917-1928.
4. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, et al. (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. The New England journal of medicine 329: 1524-1530.
5. Bayry J, Negi VS, Kaveri SV, (2011) Intravenous immunoglobulin therapy in rheumatic diseases. Nature reviews Rheumatology 7: 349-359.
6. Kazatchkine MD, Kaveri SV, (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. The New England journal of medicine 345: 747-755.
7. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV, (2003) Intravenous immunoglobulin for infectious diseases: tailor-made or universal? The Journal of infectious diseases 188: 1610.
8. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV, (2004) Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends in pharmacological sciences 25: 306-310.
9. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, et al. (2003) Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. The Journal of infectious diseases 188: 5-12.
10. Krause I, Wu R, Sherer Y, Patanik M, Peter JB, et al. (2002) In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations-a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfusion medicine 12: 133-139.
11. Siber GR, Leombruno D, Leszczynski J, McIver J, Bodkin D, et al. (1994) Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. The Journal of infectious diseases 169: 1368-1373.
12. Rabel PO, Planitzer CB, Farcet MR, Kreil TR, (2012) Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations. Clinical and vaccine immunology 19: 623-625.
13. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, et al. (2001) CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nature immunology 2: 732-738.
14. Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, et al. (2009) Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. Journal of immunology 183: 6338-6345.
15. Choi Y, Mason CS, Jones LP, Crabtree J, Jorquera PA, et al. (2012) Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral immunology 25: 193-203.
16. Caidi H, Harcourt JL, Tripp RA, Anderson LJ, Haynes LM, (2012) Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice. PloS one 7: e51485.
17. Haynes LM, Caidi H, Radu GU, Miao C, Harcourt JL, et al. (2009) Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. The Journal of infectious diseases 200: 439-447.
18. Miao C, Radu GU, Caidi H, Tripp RA, Anderson LJ, et al. (2009) Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in mice. The Journal of general virology 90: 1119-1123.
19. Levine S, Klaiber-Franco R, Paradiso PR, (1987) Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. The Journal of general virology 68 (Pt 9): 2521-2524.
20. Bukreyev A, Yang L, Collins PL, (2012) The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement. Journal of virology 86: 10880-10884.
21. Kaul TN, Welliver RC, Ogra PL, (1982) Development of antibody-dependent cell-mediated cytotoxicity in the respiratory tract after natural infection with respiratory syncytial virus. Infection and immunity 37: 492-498.
22. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, et al. (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nature reviews Drug discovery 10: 101-111.
23. Spycher M, Matozan K, Minnig K, Zehnder R, Miescher S, et al. (2009) In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations. Vox sanguinis 97: 348-354.
24. Sung CC, Chi H, Chiu NC, Huang DT, Weng LC, et al. (2011) Viral etiology of acute lower respiratory tract infections in hospitalized young children in Northern Taiwan. Journal of microbiology, immunology, and infection 44: 184-190.
25. Stiehm ER, Roberts RL, Ank BJ, Plaeger-Marshall S, Salman N, et al. (1994) Comparison of cytotoxic properties of neonatal and adult neutrophils and monocytes and enhancement by cytokines. Clinical and diagnostic laboratory immunology 1: 342-347.
26. Nguyen QH, Roberts RL, Ank BJ, Lin SJ, Lau CK, et al. (1998) Enhancement of antibody-dependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12. Clinical and diagnostic laboratory immunology 5: 98-104.